Drug Trial Radar · NCT07778316
Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Aug 28, 2026
Primary completion
Sep 24, 2027
Study completion Jul 30, 2030
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Aug 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to demonstrate non-inferiority in pharmacokinetic (PK) parameters of subcutaneous (SC) vs intravenous (IV) tarlatamab administration and to characterize the efficacy, safety, and tolerability of SC tarlatamab in participants with relapsed extensive-stage small-cell lung cancer (ES-SCLC) after platinum-based chemotherapy.
Conditions
- Small Cell Lung Cancer
Interventions
TarlatamabDrug
Administered via SC injection or IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Curve From Cycle 2 Day 1 to Day 15 (AUC C2D1-D15) of TarlatamabTime frame: From Cycle 2 Day 1 to Day 15 (each cycle is 28 days)
- Predose Concentration (Ctrough) of TarlatamabTime frame: On Cycle 2 Day 15 (each cycle is 28 days)
Locations
9 sites in 5 countries. Site status is shown where the registry gives one.
University of Florida Health Cancer Center at Orlando Health
Orlando, Florida · Recruiting
Cancer and Hematology Centers of Western Michigan
Grand Rapids, Michigan · Recruiting
Oncology Hematology West PC
Omaha, Nebraska · Recruiting
Lyell McEwin Hospital
Elizabeth Vale, South Australia, Australia · Recruiting
Shanghai Pulmonary Hospital
Shanghai, China · Recruiting
Beijing Chaoyang Hospital
Beijing, Beijing Municipality, China · Recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Tokyo Metropolitan Komagome Hospital
Bunkyo-ku, Tokyo, Japan · Recruiting
Universitaetsspital Zuerich
Zurich, Switzerland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.